5/7/24 - Omalizumab and Other Food Allergy Therapeutics on the Horizon

Dr. Sharon Chinthrajah
Associate Professor, Acting Director of the Sean N. Parker Center for Allergy & Asthma Research
Stanford University
PRESENTATION OBJECTIVES:
1. Describe the clinical findings that led to the FDA approval of omalizumab for food allergy
2. Understand the clinical application of omalizumab for food allergy
3. Recognize therapeutic strategies on the horizon such as dupilumab and BTK inhibitors
DISCLOSURES:
Grant support from the Consortium for Food Allergy Research (CoFAR), National Institute of Allergy and Infectious Disease (NIAID), Food Allergy Research & Education (FARE)
Advisory board member for Alladapt Immunotherapeutics, Novartis, Allergenis, Intrommune Therapeutics, Phylaxis, and Genentech.